Aroa Biosurgery's (ASX:ARX) secured regulatory approvals to market and sell the Endoform and Myriad Matrix products in Argentina and Endoform in Egypt, according to a Tuesday filing with the Australian bourse.
Endoform was developed for the management of acute and chronic wounds, while Myriad Matrix is used in soft tissue reconstruction and complex wounds.
The soft tissue regeneration firm's cash receipts rose 35% to NZ$19.9 million in the second quarter ended Sept. 30, compared with the previous comparable period, the filing added.
Shares of Aroa Biosurgery rallied almost 12% at market close.
Price (AUD): $0.58, Change: $+0.060, Percent Change: +11.54%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。